BVDV vaccine
The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhea and to methods for the preparation of such vaccines.
1. A combination vaccine for the protection against Bovine Viral Diarrhea Virus (BVDV) that comprises a first live attenuated BVDV, a second live attenuated BVDV, and a pharmaceutically acceptable carrier;
wherein the first BVDV and the second BVDV are either both Type 1 BVDVs or both Type 2 BVDVs;
wherein the first BVDV and the second BVDV each comprise a BVDV E2 gene; and
wherein when the first BVDV and the second BVDV are both Type 1 BVDVs, the E2 gene of the second BVDV is replaced by a BVDV E2 gene of a Type 2 BVDV; and wherein when the first BVDV and the second BVDV are both Type 2 BVDVs, the E2 gene of the second BVDV is replaced by a BVDV E2 gene of a Type 1 BVDV.
2. A combination vaccine for the protection against Bovine Viral Diarrhea Virus (BVDV) that comprises a first live attenuated BVDV, a second live attenuated BVDV, and a pharmaceutically acceptable carrier;
wherein the first BVDV and the second BVDV are either both Type 1 BVDVs or both Type 2 BVDVs;
wherein the first BVDV and the second BVDV each comprise a BVDV E1 gene and a BVDV E2 gene; and
wherein when the first BVDV and the second BVDV are both Type 1 BVDVs, both the BVDV E2 gene and the BVDV E1 gene of the second BVDV are replaced by a BVDV E2 gene and a BVDV E1 gene of a Type 2 BVDV; and wherein when the first BVDV and the second BVDV are both Type 2 BVDVs, both the E2 and the E1 gene of the second BVDV is replaced by a BVDV E2 and BVDV E1 gene of a Type 1 BVDV.
3. The combination vaccine according to claim 1 , wherein the backbone of the first and second BVDV belongs to a Type 1 BVDV and the BVDV E2 gene of the second BVDV belongs to a Type 2 BVDV.
4. The combination vaccine according to claim 1 , wherein the backbone of the first and second BVDV belongs to a Type 2 BVDV and the BVDV E2 gene of the second BVDV belongs to a Type 1 BVDV.
5. The combination vaccine according to claim 1 , characterised in that said first BVDV and said second BVDV have the same backbone.
6. The combination vaccine according to claim 5 , characterised in that said backbone is BNDV a Type 1 BVDV.
7. The combination vaccine according to claim 1 , wherein said first BVDV or said second BVDV comprises a deletion in a gene selected from the group consisting of the N pro gene and the E rns gene.
8. The combination vaccine according to claim 1 , characterized in that said vaccine or combination vaccine comprises an additional antigen of a virus or micro-organism pathogenic to ruminants, an antibody against said antigen or genetic information encoding an immunogenic polypeptide of said virus or micro-organism.
9. The combination vaccine according to claim 8 , characterized in that said virus or micro-organism pathogenic to ruminants is selected from the group of Bovine Rotavirus, Bovine Herpesvirus, Parainfluenza Type 3 virus, Bovine Paramyxovirus, Bluetongue virus, Foot and Mouth Disease virus, Pasteurella haemolytica and Bovine Respiratory Syncytial Virus.
10. The combination vaccine according to claim 1 , characterised in that it is in a freeze-dried form.
11. A method for making a combination vaccine according to claim 1 , comprising the step of mixing a live attenuated Type 1 BVDV that comprises a Type 1 BVDV E2 gene, a live attenuated Type 1 BVDV that comprises a Type 2 BVDV E2 gene in place of a Type 1 BVDV E2 gene, and a pharmaceutically acceptable carrier.
12. The combination vaccine according to claim 2 , wherein the backbone of the first and second BVD virus belongs to a Type 1 BVDV and the BVDV E2 gene of the second BVD virus belongs to a Type 2 BVDV.
13. The combination vaccine according to claim 12 , wherein said first BVDV and said second BVDV have the same backbone.
14. The combination vaccine according to claim 13 , wherein said first BVDV or said second BVDV comprises a deletion in a gene selected from the group consisting of the N pro gene and the E rns gene.
15. The combination vaccine according to claim 2 , characterised in wherein the backbone of the first and second BVD virus belongs to a Type 2 BVDV and the BVDV E2 gene and E1 gene of the second BVD virus belongs to a Type 1 BVDV.
16. A method for making a combination vaccine according to claim 1 , comprising the step of mixing a live attenuated Type 2 BVDV that comprises a Type 2 BVDV E2 gene, a live attenuated Type 2 BVDV that comprises a Type 1 BVDV E2 gene in place of a Type 2 BVDV E2 gene, and a pharmaceutically acceptable carrier.